AbbVie overcame the loss of exclusivity for its blockbuster drug Humira by successfully growing sales of new drugs Skyrizi and Rinvoq, alongside strategic acquisitions like Allergan. Over the past decade, a $1,000 investment in AbbVie grew to $7,464, outperforming the S&P 500, helped by a dividend that tripled since 2016. The company faces risks from declining sales of older drugs and high valuation, but its strong dividend growth and pipeline expansion make it attractive for long-term income investors. Future growth depends on continued success of new drugs and the integration of recent acquisitions.
AbbVie shares trade near their 52-week high of $289.00, priced at $288.21 as of Oct 30, 2026 00:31 WIB on Pluang, showing a modest 0.65% gain over the day. Despite a high market cap of $505.38 billion, the stock offers a dividend yield of 2.42%, which complements its recent growth story. Notably, most Pluang users are selling (82%) rather than buying (18%), reflecting mixed sentiment despite AbbVie's strong long-term performance.
Four NYSE-listed dividend stocks—UPS, AbbVie, Chevron, and Realty Income—are highlighted for their reliable dividends supported by strong cash flow and long histories of payouts. UPS offers a high yield of about 6.24% with improving dividend coverage...
AbbVie Inc. is trading at all-time highs with a market cap over $500 billion, supported by robust 2026 guidance. The company's Q3 earnings are expected to outperform, mainly due to strong sales from immunology drugs Skyrizi and Rinvoq, projected to g...
AbbVie has submitted a Biologics License Application to the FDA for etentamig, a second-generation bispecific antibody T-cell engager for relapsed or refractory multiple myeloma. In the Phase 3 CERVINO study, etentamig demonstrated significant improv...
AbbVie will report its Q3 2026 earnings before market open on October 30, with shares up 28.55% year to date. Options pricing suggests a roughly 5% price move around the release, indicating high expectations. The company recently trimmed its full-yea...
